As a small, privately held biotech, the Australian venture Implicit Bioscience believes its business model has a number of advantages, low risk being chief among them.
The firm has so far received much of its funding from wealthy individual investors, making it relatively immune to the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?